

## MOZOBIL (plerixafor) PRIOR AUTHORIZATION FORM

Prior authorization guidelines for Mozobil (plerixafor) and Quantity Limits/Daily Dose Limits are available on the DHS Pharmacy Services website at <u>https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/default.aspx</u>.

New request Renewal request	# of pages:	Prescriber name:		
Name of office contact:		Specialty:		
Contact's phone number:		NPI:	State license #:	
LTC facility contact/phone:		Street address:		
Beneficiary name:		City/state/zip:		
Beneficiary ID#:	DOB:	Phone:	Fax:	

## CLINICAL INFORMATION

Mozobil 24 mg/1.2 ml (20 mg/ml) single-dose vial			Beneficiary's weight:			
Drug requested:						
Dose/directions:			Quantity:	Refills:		
Diagnosis ( <u>submit documentation</u> ):			Dx code ( <u>required</u> ):			
Does the beneficiary have a diagnosis of non-Hodgkin lymphoma, multiple			$\Box$ Yes $\rightarrow$ Submit documentation of diagnosis.			
			$\square$ No $ ightarrow$ Submit documentation of diagnosis and			
consensus quidelines (e.g. NCCN_ASCO)?			medical literature supporting the use of Mozobil for			
			the beneficiary's diagnosis.			
Will the hereficient receive a CCE (colony stimulating factor, e.g., filmestim			Submit documentation of beneficiary's			
Will the beneficiary receive a CSF (colony stimulating factor, e.g., filgrastim, pegfilgrastim) in addition to Mozobil? (Note: All CSFs require prior			Yes hematopoietic cell mobilization			
authorization with Medical Assistance.)			No treatment plan, including all drugs that			
			will be used.			
If the beneficiary will be undergoing an autologous hematopoietic stem cell		Date <sup>.</sup>	Date: Submit documentation.			
transplant, what is the planned date for the beneficiary's transplant (if known)?		Dute				
PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION						
Prescriber Signature:			Date:			

<u>Confidentiality Notice</u>: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.